Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program

CONCLUSION: A multidisciplinary collaboration is recommended to facilitate the use of CYP2C19 genotype-guided antiplatelet therapy in patients with cardiovascular and cerebrovascular diseases. Evolving clopidogrel pharmacogenetic evidence necessitates thoughtful iteration of implementation efforts and strategies to optimize long-term maintenance and sustainability.PMID:38253063 | DOI:10.1093/ajhp/zxae008

Source: American Journal of Health-System Pharmacy : AJHP - January 22, 2024 Category: Drugs & Pharmacology Authors: Christina L Aquilante Katy E Trinkley Yee Ming Lee Kristy R Crooks Emily C Hearst Simeon M Heckman Kaitlyn W Hess Elizabeth L Kudron James L Martin Carolyn T Swartz David P Kao Source Type: research